These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 27853068

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K.
    World J Gastroenterol; 2017 Aug 07; 23(29):5379-5385. PubMed ID: 28839438
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.
    World J Gastroenterol; 2014 Aug 28; 20(32):11400-5. PubMed ID: 25170228
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T.
    Dig Dis; 2018 Aug 28; 36(4):314-321. PubMed ID: 29852495
    [Abstract] [Full Text] [Related]

  • 8. [Management of ascites in cirrhotic patients].
    Kurosaki M, Nakanishi H, Izumi N.
    Nihon Shokakibyo Gakkai Zasshi; 2017 Aug 28; 114(1):27-34. PubMed ID: 28070092
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I.
    Expert Rev Gastroenterol Hepatol; 2014 Jul 28; 8(5):461-70. PubMed ID: 24678622
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M.
    World J Gastroenterol; 2017 Dec 07; 23(45):8062-8072. PubMed ID: 29259382
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, Sata M, Yoshihara H, Ono N, Murawaki Y.
    J Gastroenterol; 2010 Sep 07; 45(9):979-87. PubMed ID: 20387081
    [Abstract] [Full Text] [Related]

  • 13. [Effect of tolvaptan on ascites due to malignancy].
    Mitsuhashi N, Nemoto S, Satoh Y, Aoki Y, Teranaka R, Sasaki K, Shimazaki R, Ueda A, Nishino H, Akiyama T, Hosokawa I, Yoichi T, Kawamoto J, Kuboki S, Yoshitomi H, Kato A, Shimizu Y, Ohtsuka M, Shimizu H, Miyazaki M.
    Gan To Kagaku Ryoho; 2015 Feb 07; 42(2):201-5. PubMed ID: 25743139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K, ASCITES 14-Day Administration Study Group.
    J Int Med Res; 2013 Jun 07; 41(3):835-47. PubMed ID: 23685892
    [Abstract] [Full Text] [Related]

  • 16. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
    Nagayama I, Masuda T, Nakagawa S, Murakami T, Ohara K, Matsuoka R, Kobayashi T, Maeshima A, Akimoto T, Saito O, Muto S, Nagata D.
    Intern Med; 2019 Jun 01; 58(11):1587-1591. PubMed ID: 30713322
    [Abstract] [Full Text] [Related]

  • 17. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I, Terai S, Nakajima K, Shibasaki Y, Tachikawa S, Tsubouchi H.
    J Gastroenterol; 2017 Feb 01; 52(2):229-236. PubMed ID: 27379386
    [Abstract] [Full Text] [Related]

  • 18. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y.
    Dig Dis; 2019 Feb 01; 37(3):239-246. PubMed ID: 30625470
    [Abstract] [Full Text] [Related]

  • 19. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study.
    Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K, ASCITES Clinical Pharmacology Group.
    J Int Med Res; 2012 Feb 01; 40(6):2381-93. PubMed ID: 23321196
    [Abstract] [Full Text] [Related]

  • 20. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.